[212Pb]Pb-ADVC003

[212Pb]Pb-ADVC003 is a targeted alpha radioligand therapy under preclinical development by AdvanCell Isotopes for the treatment of cancers, specifically breast and pancreatic cancer. The drug utilizes the radioisotope lead-212 (²¹²Pb), which emits alpha particles to deliver ionizing radiation directly to tumor cells, aiming to maximize tumor cell kill while minimizing damage to surrounding healthy tissue. This approach leverages AdvanCell’s proprietary technology for reliable supply and conjugation of lead-212, enabling next-generation radiopharmaceuticals for oncology indications[1][2][9]. The mechanism of action is based on the emission of ionizing radiation from the radioactive isotope, resulting in DNA damage and subsequent cell death in targeted cancer cells[1][2].